The ongoing ALNEO study aims to evaluate the efficacy of alectinib as neoadjuvant therapy in patients with surgically resectable stage III ALK-positive NSCLC (Leonetti et al., 2021). The gene discussed is ALK; the disease is non-small cell lung carcinoma.